{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T21:27:34Z","timestamp":1793482054209,"version":"4.5.0"},"reference-count":96,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2025,1,12]],"date-time":"2025-01-12T00:00:00Z","timestamp":1736640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Huntington's Disease"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:p>Huntington's disease (HD) is a progressive neurodegenerative disorder marked by motor, cognitive, and behavioral impairments. Antidopaminergic medications (ADMs), such as VMAT2 inhibitors and antipsychotics, are commonly used to manage HD motor disturbances and behavioral disorders. For patients and caregivers, ADMs are an important tool for managing symptoms that negatively affect daily life. However, the impact of ADM use in HD is not firmly understood due to a lack of robust, systematic studies that assessed their overall effect on HD disease. A mounting body of evidence suggests these medications may be associated with worse clinical measures of cognitive function and functional impairment. While regulatory guidelines highlight adverse effects like sedation, cognitive dysfunction, and extrapyramidal symptoms, it is unclear whether ADMs directly impact disease progression or if the side effects mimic or exacerbate measures of HD symptoms in clinical trials. Given ADM effects on the central nervous system and biological uncertainty within HD outcomes, clinical trial designs should recognize the impact of ADMs on key outcomes, as measured by acceptable scales including Total Functional Capacity, Stoop Word Reading, Symbol Digit Modality Test, and the composite Unified Huntington's Disease Rating Scale. The development of novel HD interventions requires consideration of concomitant ADM use that may influence measures of disease presentation. In this review, we highlight the role of ADMs in HD management, their symptomatic benefits and potential risks, especially with high dose associated side effects, interactions with CYP2D6 inhibitors, and the individualized need for careful dose monitoring for clinical care and trial design.<\/jats:p>","DOI":"10.1177\/18796397241304312","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T02:36:47Z","timestamp":1736735807000},"page":"16-29","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":8,"title":["Antidopaminergic medications in Huntington's disease"],"prefix":"10.1177","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0099-8814","authenticated-orcid":false,"given":"Andrew M","family":"Tan","sequence":"first","affiliation":[{"name":"Prilenia Therapeutics B.V., Naarden, The Netherlands"},{"name":"Department of Neurology, Yale University School of Medicine, New Haven, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Geva","sequence":"additional","affiliation":[{"name":"Prilenia Therapeutics B.V., Naarden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y Paul","family":"Goldberg","sequence":"additional","affiliation":[{"name":"Prilenia Therapeutics B.V., Naarden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk","family":"Schuring","sequence":"additional","affiliation":[{"name":"Prilenia Therapeutics B.V., Naarden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd-Jan","family":"Sanson","sequence":"additional","affiliation":[{"name":"Prilenia Therapeutics B.V., Naarden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Rosser","sequence":"additional","affiliation":[{"name":"Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, University of British Columbia, Vancouver, Canada"},{"name":"School of Biosciences Life Sciences Building, Cardiff University Brain Repair Group, Cardiff, UK"},{"name":"Advanced Neurotherapeutics Centre, Neuroscience and Mental Health Innovation Institute, Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Raymond","sequence":"additional","affiliation":[{"name":"Departments of Psychiatry and Medicine, University of British Columbia, Djavad Mowafaghian Centre for Brain Health, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Reilmann","sequence":"additional","affiliation":[{"name":"Section for Neurodegenerative Diseases, Department of Neurology, Hertie Institute for Clinical Brain Research, University of T\u00fcbingen, Germany"},{"name":"Institute of Clinical Radiology, University of M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R","family":"Hayden","sequence":"additional","affiliation":[{"name":"Prilenia Therapeutics B.V., Naarden, The Netherlands"},{"name":"Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, University of British Columbia, Vancouver, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2084-6869","authenticated-orcid":false,"given":"Karen","family":"Anderson","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Department of Neurology, Georgetown University, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,1,12]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-020-0389-4"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-022-11418-y"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2019-322038"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.3233\/JHD-150143"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.624104"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.31.10.1333"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.54.2.452"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30448-4"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11123336"},{"key":"e_1_3_4_11_2","first-page":"1520","article-title":"Natural history of Huntington disease","volume":"70","author":"Dorsey ER","year":"2013","unstructured":"Dorsey ER, Beck CA, Darwin K, et al. Natural history of Huntington disease. JAMA Neurol 2013; 70: 1520\u20131530.","journal-title":"JAMA Neurol"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23337"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2014.24"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00120-X"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30124-2"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.29027"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.28489"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.595679"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.92.15_supplement.P1.8-043"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.00710"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(19)30153-X"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26014"},{"key":"e_1_3_4_23_2","unstructured":"Ingrezza (valbenazine) [package insert]. Neurocrine Biosciences Inc."},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/9781119870203"},{"key":"e_1_3_4_25_2","article-title":"Therapeutic interventions for symptomatic treatment in Huntington\u2019s disease","volume":"3","author":"Mestre T","year":"2009","unstructured":"Mestre T, Ferreira J, Coelho MM, et al. Therapeutic interventions for symptomatic treatment in Huntington\u2019s disease. Cochrane Database Syst Rev 2009; 3: CD006456.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318263c443"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.3233\/JHD-180293"},{"key":"e_1_3_4_28_2","unstructured":"Austedo (deutetrabenazine) [package insert]. Teva Pharmaceuticals USA Inc. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208082s000lbl.pdf (2017)."},{"key":"e_1_3_4_29_2","unstructured":"Xenazine (tetrabenazine) [package insert]. Lundbeck."},{"key":"e_1_3_4_30_2","unstructured":"Xenazine - Summary of Product Characteristics (SmPC) - (emc) https:\/\/www.medicines.org.uk\/emc\/product\/12643\/smpc#gref (accessed 12 August 2024)."},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2022.11.004"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1037\/0894-4105.21.1.31"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2014.1054"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrn1926"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004743"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.2015.1025383"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-444-63425-2.00010-6"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51252"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.12442"},{"key":"e_1_3_4_40_2","article-title":"Observing Huntington\u2019s disease: the European Huntington\u2019s disease network\u2019s registry","volume":"2","author":"Orth M","year":"2010","unstructured":"Orth M, Handley OJ, Schwenke C, et al. Observing Huntington\u2019s disease: the European Huntington\u2019s disease network\u2019s registry. PLoS Curr 2010; 2: RRN1184.","journal-title":"PLoS Curr"},{"key":"e_1_3_4_41_2","article-title":"Medication use in early-HD participants in Track-HD: an investigation of its effects on clinical performance","volume":"8","author":"Keogh R","year":"2016","unstructured":"Keogh R, Frost C, Owen G, et al. Medication use in early-HD participants in Track-HD: an investigation of its effects on clinical performance. PLoS Curr 2016; 8: ecurrents.hd.8060298fac1801b01ccea6acc00f97cb.","journal-title":"PLoS Curr"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005817"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2019-320646"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2012.09.022"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0085430"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00127-8"},{"key":"e_1_3_4_47_2","first-page":"162","article-title":"Medication-induced tardive dyskinesia: a review and update","volume":"17","author":"Cornett EM","year":"2017","unstructured":"Cornett EM, Novitch M, Kaye AD, et al. Medication-induced tardive dyskinesia: a review and update. Ochsner J 2017; 17: 162\u2013174.","journal-title":"Ochsner J"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000198586.85250.13"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.8655"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1371\/currents.RRN1260"},{"key":"e_1_3_4_51_2","unstructured":"FDA. The Voice of the Patient. 2016."},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-9-62"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-022-00956-8"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.2174\/138161206777698693"},{"key":"e_1_3_4_55_2","unstructured":"Risperdal (risperidone) [package insert]. Janssen Pharmaceuticals Inc."},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2015.00225"},{"key":"e_1_3_4_57_2","unstructured":"Aripiprazole (Abilify Asimtufii) [package insert]. Otsuka America Pharmaceutical Inc..pdf."},{"key":"e_1_3_4_58_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp-rj.2022.180207"},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.621691"},{"key":"e_1_3_4_60_2","unstructured":"Clozaril (clozapine) [package insert]. HLS Therapeutics (USA) Inc."},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1972.tb103717.x"},{"key":"e_1_3_4_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(79)90499-0"},{"key":"e_1_3_4_63_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.161.3.414"},{"key":"e_1_3_4_64_2","unstructured":"EMA package insert info risperidone."},{"key":"e_1_3_4_65_2","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2010.199"},{"key":"e_1_3_4_66_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002130051102"},{"key":"e_1_3_4_67_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881105048889"},{"key":"e_1_3_4_68_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-023-04552-y"},{"key":"e_1_3_4_69_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-023-02203-y"},{"key":"e_1_3_4_70_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2019.107704"},{"key":"e_1_3_4_71_2","volume-title":"Stahl\u2019s essential psychopharmacology: Neuroscientific basis and practical applications","author":"Stahl SM","year":"2013","unstructured":"Stahl SM. Stahl\u2019s essential psychopharmacology: Neuroscientific basis and practical applications. 4th ed. New York, NY, US: Cambridge University Press, 2013.","edition":"4"},{"key":"e_1_3_4_72_2","doi-asserted-by":"publisher","DOI":"10.1254\/jjp.69.399"},{"key":"e_1_3_4_73_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300203"},{"key":"e_1_3_4_74_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-9338(00)00526-5"},{"key":"e_1_3_4_75_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200140070-00003"},{"key":"e_1_3_4_76_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199447060-00009"},{"key":"e_1_3_4_77_2","unstructured":"Zyprexa (olanzapine) [package insert]. Eli Lilly and Company."},{"key":"e_1_3_4_78_2","unstructured":"Seroquel (quetiapine) [package insert]. Astrazeneca.pdf."},{"key":"e_1_3_4_79_2","doi-asserted-by":"publisher","DOI":"10.1039\/D1CP01637G"},{"key":"e_1_3_4_80_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.155.7.921"},{"key":"e_1_3_4_81_2","doi-asserted-by":"publisher","DOI":"10.1177\/1941875210386491"},{"key":"e_1_3_4_82_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0874-x"},{"key":"e_1_3_4_83_2","unstructured":"Tetrabenazine [package insert]. AOP Orphan Pharmaceuticals AG."},{"key":"e_1_3_4_84_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13317"},{"key":"e_1_3_4_85_2","doi-asserted-by":"publisher","DOI":"10.3390\/genes11111295"},{"key":"e_1_3_4_86_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2021.05.013"},{"key":"e_1_3_4_87_2","unstructured":"Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017 - PubMed https:\/\/pubmed.ncbi.nlm.nih.gov\/29390205\/ (accessed 25 August 2024)."},{"key":"e_1_3_4_88_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.882"},{"key":"e_1_3_4_89_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-021-03202-0"},{"key":"e_1_3_4_90_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1M582"},{"key":"e_1_3_4_91_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-200209000-00007"},{"key":"e_1_3_4_92_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-1331.2002.0354e.x"},{"key":"e_1_3_4_93_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-200203000-00009"},{"key":"e_1_3_4_94_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.678484"},{"key":"e_1_3_4_95_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.96.15_supplement.2247"},{"key":"e_1_3_4_96_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.1034269"},{"key":"e_1_3_4_97_2","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbad002"}],"container-title":["Journal of Huntington's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/18796397241304312","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/18796397241304312","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/18796397241304312","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:56:31Z","timestamp":1777452991000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/18796397241304312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,12]]},"references-count":96,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1177\/18796397241304312"],"URL":"https:\/\/doi.org\/10.1177\/18796397241304312","relation":{},"ISSN":["1879-6397","1879-6400"],"issn-type":[{"value":"1879-6397","type":"print"},{"value":"1879-6400","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,12]]}}}